Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
fda
indiana blog main
3
×
indiana top stories
life sciences
national blog main
new york blog main
new york top stories
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
europe blog main
europe top stories
national
national top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alnylam pharmaceuticals
ambys medicines
amicus therapeutics
ampio pharmaceuticals
angelman syndrome
arena pharmaceuticals
athenex
biomarin pharmaceutical
bluebird bio
What
drug
fda
3
×
patients
3
×
approval
aren’t
bid
bio
boehringer
cancer
developers
diabetes
drugs
eisai
eli
expand
fallen
flags
gene
help
higher
imminent
incidence
ingelheim
lilly
long
lorcaserin
loss
market
marketed
marketing
medicare
medicine
medicine’s
moves
news
noteworthy
post
prices
pulls
rejects
Language
unset
Current search:
patients
×
fda
×
" indiana blog main "
×
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More